HSV2 gB Antibody
Description
Product Specs
Herpes simplex virus (HSV) enters host cells through a multi-step process involving viral glycoproteins and cellular receptors. The virus's outer envelope contains proteins that bind to specific receptors on the host cell's surface. This binding triggers the fusion of the viral envelope with the cell membrane, creating a pore. Through this pore, the virus enters the host cell. HSV entry mirrors the entry mechanisms of other viruses. Initially, matching receptors on the virus and the cell surface draw the two membranes close. An intermediate stage involves the merging of the two membranes, forming a partially fused state called hemifusion. Finally, a stable entry pore forms, allowing the contents of the viral envelope to enter the host cell.
The antibody is supplied in a solution containing 1 milligram of antibody per milliliter of phosphate-buffered saline (PBS) at a pH of 7.2. The solution also contains 0.01% sodium azide (NaN3) as a preservative.
For short-term storage (2-4 weeks), the antibody should be kept at a temperature of 4 degrees Celsius. For long-term storage, the antibody should be stored frozen at -20 degrees Celsius. To maintain antibody stability, it is crucial to minimize the number of times the antibody is thawed and refrozen.
HSV-2 gB antibody was purified from mouse ascitic fluids by Protein-A chromatography.
Mouse Anti Human Monoclonal.
Monoclonal anti HSV-2 gB IgG1 produced against a HSV-2 infected cells.
Product Science Overview
Herpes Simplex Virus Type 2 (HSV-2) is a member of the Herpesviridae family, which is known for causing genital herpes in humans. One of the key components of HSV-2 is Glycoprotein B (gB), a crucial protein involved in the virus’s ability to enter host cells and facilitate cell-to-cell transmission. This article delves into the background of HSV-2 gB and the development of mouse anti-human antibodies targeting this glycoprotein.
Glycoprotein B (gB) is an envelope glycoprotein that plays a pivotal role in the viral life cycle of HSV-2. It is involved in the initial attachment of the virus to host cells, fusion of the viral envelope with the host cell membrane, and subsequent entry into the host cell. gB is also essential for the spread of the virus between cells, making it a critical target for therapeutic interventions .
Mouse anti-human antibodies are monoclonal antibodies developed in mice that specifically target human proteins. These antibodies are produced using hybridoma technology, where mice are immunized with the target antigen (in this case, HSV-2 gB), and antibody-producing B cells are fused with myeloma cells to create hybrid cells capable of producing large quantities of the desired antibody .
The development of mouse anti-human antibodies targeting HSV-2 gB involves several steps:
- Immunization: Mice are immunized with HSV-2 gB to elicit an immune response.
- Hybridoma Creation: B cells from the immunized mice are fused with myeloma cells to create hybridomas.
- Screening: Hybridomas are screened for the production of antibodies that specifically bind to HSV-2 gB.
- Purification: The selected antibodies are purified and characterized for their specificity and affinity .
These antibodies have several applications in research and clinical settings:
- Diagnostic Tools: They can be used in assays such as ELISA and Western blotting to detect the presence of HSV-2 gB in samples.
- Therapeutic Potential: By targeting gB, these antibodies can potentially neutralize the virus and prevent its spread, offering a therapeutic approach for HSV-2 infections.
- Research: They are valuable tools for studying the structure and function of gB, as well as the mechanisms of HSV-2 entry and transmission .
